Rapid Serological Tests for SARS-CoV-2: Diagnostic Performance of 4 Commercial Assays
Authors:
Open Access
- 22 April 2021
- journal article
- research article
- Published by S. Karger AG in Medical Principles and Practice
- Vol. 30 (4) , 385-394
Abstract
Objective: To assess the diagnostic performance of lateral flow immunochromatographic assays (LFAs) of 4 different manufacturers to identify SARS-CoV-2 antibodies (IgM, IgG, or total), comparing them with the nucleic acid amplification test (NAAT) or the clinical defined test (definite or probable SARS-CoV-2 infection, respectively). Methods: One hundred nineteen serum samples were randomly selected by convenience and distributed in the following groups: (1) group with SARS-CoV-2 infection (n = 82; RT-qPCR positive [definite, n = 70] and probable [n = 12]); (2) other diseases (n = 27; other viruses identified [n = 8] and SARS of other etiologies [n = 19]); and (3) healthy control group (n = 10). LFAs of 4 manufacturers were compared: MedTest Coronavirus (COVID-19) IgG/IgM (MedLevensohn, Brazil); COVID-19 IgG/IgM ECO Test (Ecodiagnóstica, Brazil); Camtech COVID-19 IgM/IgG Rapid Test Kit (Camtech Diagnostics Pte Ltd, Singapore); and 1-Step COVID-19 Test for total antibodies (Guangzhou Wondfo Biotech Co., China). Results: The 4 tests studied showed high diagnostic performance characteristics for the diagnoses of definite or probable SARS-CoV-2 infection. The best measures were for the Wondfo test: sensitivity (86.59%; 95% CI: 77.26–93.11%), specificity (100%; 90.51–100%), DOR (257; 60–1,008), LR+ (33.43; 4.82–231.85), LR− (0.13; 0.08–0.23), accuracy (90.76%; 84.06–95.29%), and Matthews correlation coefficient (MCC) 0.82. Although considering only the probable SARS-CoV-2 infection (PCR−) cases, all the kits studied showed limited values. Conclusion: Our data demonstrate the excellent performance of LFA for the diagnoses of definite or probable SARS-CoV-2 infection. There was substantial heterogeneity in sensitivities of IgM and IgG antibodies among the different kits. LFA tests cannot replace molecular diagnostics but should be used as an additional screening tool.Keywords
All Related Versions
This publication has 19 references indexed in Scilit:
- Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patientsJournal of Infection, 2020
- Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort studyThe Lancet Infectious Diseases, 2020
- Performance of VivaDiag COVID‐19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID‐19 in acute patients referring to emergency room departmentJournal of Medical Virology, 2020
- Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)Clinical Infectious Diseases, 2020
- Development and clinical application of a rapid IgM‐IgG combined antibody test for SARS‐CoV‐2 infection diagnosisJournal of Medical Virology, 2020
- Better Tests, Better Care: Improved Diagnostics for Infectious DiseasesClinical Infectious Diseases, 2013
- Sensitivity × PPV is a recognized test called the clinical utility index (CUI+)European Journal of Epidemiology, 2011
- The clinical significance of subjective memory complaints in the diagnosis of mild cognitive impairment and dementia: a meta‐analysisInternational Journal of Geriatric Psychiatry, 2008
- Understanding diagnostic tests 2: likelihood ratios, pre‐ and post‐test probabilities and their use in clinical practiceActa Paediatrica, 2007
- Simplifying likelihood ratiosJournal of General Internal Medicine, 2002